Esophageal Cancer Risk Registry

Part of paid clinical trials in Pittsburgh, Pennsylvania.

Sponsor
University of Pittsburgh
Study ID
NCT00260585
Status
Recruiting
Apply to this trial

Conditions

  • Esophageal Achalasia
  • Esophageal Cancer
  • Esophageal Diseases
  • Gastroesophageal Reflux Disease (GERD)
  • Hiatal Hernia

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Survey of client health, personal habits, family history — PROCEDURE
    A questionnaire is administered at the time of consent.
  • Blood specimen for non-DNA and DNA parts — PROCEDURE
    Blood specimen is collected prior to surgery or at the time of scheduled routine surgical procedure(s), and at the time of routine follow-up visits
  • Biopsy of esophageal/stomach tissue, lymph nodes, tumor — PROCEDURE
    Tissue from the biopsies is collected intraoperatively.
  • Biopsies, oral (saliva) and/or secretions, washings or mucosal scrapings/brushing from routine clinical surveillance endoscopies — PROCEDURE
    Tissue from the biopsies, oral (saliva) and/or secretions, washings or mucosal scrapings/brushings are collected intraoperatively.

Study Details

The purpose of this study is to identify markers in the blood and tissue that could indicate risk factors for the development and progression of esophagus cancer. This research aims to collect medical history, blood, and tissue samples from patients who present with an esophageal disorder. Identifying genetic and behavioral risk factors involved in the development of esophageal cancer might allow for early detection and prevention. Survival and an opportunity for a cure with esophageal cancer will depend greatly on the stage of diagnosis. Tumors can develop changes in their genetic (hereditary) make-up, and these changes can sometimes be seen in normal tissues before the development of cancer. These genetic (hereditary) changes can serve as tumor markers and can be detected using methods that study changes in genetic material like DNA and RNA. The analysis of proteins can provide additional information. By identifying changes in these molecules that are different or altered in cancer, the investigators can use methods and tests for the detection of these changes.

Key Dates

Start date
Jun 30, 1999
Status verified
Mar 2026
Primary completion
Dec 31, 2050
Completion
Dec 31, 2050

Study Design

Enrollment
7,000 participants (estimated)

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Department of Cardiothoracic SurgeryPittsburghPennsylvania15232
Julie Ward, BSN
[email protected]
412-647-8583
James Luketich, MD (PRINCIPAL_INVESTIGATOR)
Neil Christie, MD (SUB_INVESTIGATOR)
Matthew Schuchert, MD (SUB_INVESTIGATOR)
Arjun Pennathur, MD (SUB_INVESTIGATOR)
Ryan Levy, MD (SUB_INVESTIGATOR)
Omar Awais, DO (SUB_INVESTIGATOR)
Vera Donnenberg, PhD (SUB_INVESTIGATOR)
Olivera Finn, PhD (SUB_INVESTIGATOR)
Tadeusz Witek, MD (SUB_INVESTIGATOR)
Joel Greenberger, MD (SUB_INVESTIGATOR)
Evan Alicuben, MD (SUB_INVESTIGATOR)
Navid Ajabshir, MD (SUB_INVESTIGATOR)
Renee Levesque, MD (SUB_INVESTIGATOR)
Christian Otero, MD (SUB_INVESTIGATOR)
Thomas Melvin, MD (SUB_INVESTIGATOR)
James Ackerman, MD (SUB_INVESTIGATOR)
Juan Munoz-Largacha, MD (SUB_INVESTIGATOR)

Find similar trials in Pittsburgh, PA

By condition
Esophageal cancer
By specialty
OncologyGI oncology
By research site
Department of Cardiothoracic Surgery· Pittsburgh, PA

Related Studies